Skip to main content
Media RelationsInvestor RelationsHome
Logo SphingotecLogo Sphingotec

Scientific Publications

SphingoTec's biomarker discovery is based on the highest standard of evidence, with over 100 publications, over 100 clinical studies, and more than 100.000 patients enrolled. Browse our scientific publications to learn more about how our biomarkers can impact patient care. You can use filters to narrow your search results by Year, Biomarker and Indications.

2023 bio-ADM penKid Major Surgery Other

Proenkephalin A and bioactive adrenomedullin are useful for risk prognostication in cardiac surgery

View the paper
2022 bio-ADM DPP3 COVID-19

Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: a prospective international multicentre study

View the paper
2022 bio-ADM Cardiovascular Disease Other

Association of Plasma Bioactive Adrenomedullin Levels with Cardiovascular Risk Factors in BCRA1/2 Mutation Carriers - Zusammenhang zwischen bioaktivem Adrenomedullin-Spiegel und kardiovaskulären Risikofaktoren bei BCRA1/2-Mutationsträgerinnen

View the paper
2022 bio-ADM Other

Analytical performance evaluation of bioactive adrenomedullin on point-of-care platform

View the paper
2022 bio-ADM Heart Failure

Bioactive adrenomedullin for assessment of venous congestion in heart failure

View the paper
2022 bio-ADM Sepsis Other

Can Acute Care Biomarkers change Patient´s Management in Spepsis?

View the paper
2022 bio-ADM penKid Sepsis Other

30 Days Mortality Prognostic Value of POCT Bio-Adrenomedullin and Proenkephalin in Patients with Sepsis in the Emergency Department

View the paper
2022 bio-ADM Heart Failure

Albuminuria as a marker of systemic congestion in patients with heart failure

View the paper
2022 bio-ADM Other

Biologically Active Adrenomedullin (bio-ADM) is of potential value in identifying congestion and selecting patients for neurohormonal blockade in acute dyspnea

View the paper
2022 bio-ADM Cardiovascular Disease Major Surgery

The value of bioactive adrenomedullin and dipeptidyl peptidase 3 to predict short-term unfavorable outcomes after cardiac surgery.

View the paper
2022 bio-ADM COVID-19

Adrenomedullin Therapy in Moderate to Severe COVID-19

View the paper
2022 bio-ADM DPP3 Sepsis

Identifying clinical subtypes in sepsis-survivors with different one-year outcomes: a secondary latent class analysis of the FROG-ICU cohort

View the paper
2022 bio-ADM Sepsis Other

Bioactive adrenomedullin in sepsis patients in the emergency department is associated with mortality, organ failure and admission to intensive care

View the paper
2022 bio-ADM DPP3 Sepsis

Identifying clinical subtypes in sepsis-survivors with diferent one-year outcomes: a secondary latent class analysis of the FROG-ICU cohort

View the paper
2022 bio-ADM Sepsis Other

Can Acute Care Biomarkers Change Patient’s Management in Sepsis?

View the paper
2021 bio-ADM DPP3 Heart Failure

Biomarkers in Acute Heart Failure: Diagnosis, Prognosis, and Treatment

View the paper
2021 bio-ADM Other

Bioactive adrenomedullin a prognostic biomarker in patients with mild to moderate dyspnea at the emergency department: an observational study

View the paper
2021 bio-ADM Heart Failure

Activity of the adrenomedullin system to personalise post-discharge diuretic treatment in acute heart failure

View the paper
2021 bio-ADM COVID-19

Prognostic value of bioactive adrenomedullin in critically ill patients with COVID-19 in Germany: an observational cohort study

View the paper
2021 bio-ADM Cardiogenic Shock

Elevated plasma bioactive adrenomedullin and mortality in cardiogenic shock: results from the OptimaCC trial

View the paper
2021 bio-ADM DPP3 penKid Other

Plasma proenkephalin A 119 159 and dipeptidyl peptidase 3 on admission after cardiac arrest help predict long-term neurological outcome

View the paper
2021 bio-ADM DPP3 Other

Circulating biomarkers to assess cardiovascular function in critically ill

View the paper
2021 bio-ADM Other

Levels of bioactive adrenomedullin in plasma and cerebrospinal fluid in relation to delayed cerebral ischemia in patients after aneurysmal subarachnoid hemorrhage: A prospective observational study

View the paper
2020 bio-ADM DPP3 Sepsis

Promotion of vascular integrity in sepsis through modulation of bioactive adrenomedullin and dipeptidyl peptidase 3

View the paper
2020 bio-ADM Sepsis

Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness

View the paper
2020 bio-ADM penKid Acute Kidney Injury Sepsis

The value of plasma pro-enkephalin and adrenomedullin for the prediction of sepsis-associated acute kidney injury in critically ill patients

View the paper
2020 bio-ADM Heart Failure

Increased concentrations of bioactive adrenomedullin subsequently to ARNi treatment in chronic systolic heart failure

View the paper
2020 bio-ADM Major Surgery

Postoperatively increased bioactive adrenomedullin is related to adverse outcome after complex aortic surgery

View the paper
2020 bio-ADM Heart Failure

Bioactive adrenomedullin in plasma is associated to biventricular filling pressures in patients with advanced heart failure

View the paper
2020 bio-ADM Heart Failure

Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment

View the paper
2020 bio-ADM Sepsis

Added value of serial bio-adrenomedullin measurement in addition to lactate for the prognosis of septic patients admitted to ICU

View the paper
2019 bio-ADM Heart Failure

Adrenomedullin in heart failure: pathophysiology and therapeutic application

View the paper
2019 bio-ADM Heart Failure

Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure

View the paper
2019 bio-ADM Heart Failure

Adrenomedullin, a circulating biomarker of congestion: in search of evidence

View the paper
2019 bio-ADM Heart Failure

Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission

View the paper
2019 bio-ADM Heart Failure

Bioactive adrenomedullin, proenkephalin A and clinical outcomes in an acute heart failure setting

View the paper
2019 bio-ADM Other

Bioactive adrenomedullin, organ support therapies, and survival in the critically ill: Results from the French and European Outcome Registry in ICU study

View the paper
2019 bio-ADM Sepsis

Circulating biologically active adrenomedullin predicts organ failure and mortality in sepsis

View the paper
2019 bio-ADM Heart Failure

Plasma bio-adrenomedullin is a marker of acute heart failure severity in patients with acute coronary syndrome

View the paper
2018 bio-ADM Sepsis

Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study

View the paper
2018 bio-ADM Heart Failure

Bio-adrenomedullin as a potential quick, reliable, and objective marker of congestion in heart failure

View the paper
2018 bio-ADM Sepsis

Vascular effects of adrenomedullin and the anti-adrenomedullin antibody Adrecizumab in sepsis

View the paper
2018 bio-ADM Sepsis

Adrenomedullin and adrenomedullin-targeted therapy as treatment strategies relevant for sepsis

View the paper
2018 bio-ADM Other

Determinants of long-term outcome in ICU survivors: results from the FROG-ICU study

View the paper
2017 bio-ADM Acute myocardial infarction

Prognostic value of human mature adrenomedullin in patients with acute myocardial infarction

View the paper
2017 bio-ADM Other

Sandwich immunoassay for bioactive plasma adrenomedullin

View the paper
2017 bio-ADM Cardiogenic Shock

Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock

View the paper
2017 bio-ADM Sepsis

Circulating biologically active adrenomedullin (bio-ADM) predicts hemodynamic support requirement and mortality during sepsis

View the paper
2016 bio-ADM Sepsis

Plasma adrenomedullin in critically ill patients with sepsis after major surgery: a pilot study

View the paper
2016 bio-ADM Heart Failure

Plasma bioactive adrenomedullin as a prognostic biomarker in acute heart failure

View the paper
2014 bio-ADM Sepsis

Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis

View the paper